{"news_desk": "Business", "print_page": "3", "section_name": "The Upshot", "subsection_name": null, "byline": {"original": "By PETER EAVIS", "person": [{"rank": 1, "role": "reported", "firstname": "Peter", "organization": "", "lastname": "EAVIS"}]}, "abstract": "The Upshot; compensation practices likely played role in downfall of Valeant Pharmaceuticals, drug giant that has seen shares fall some 90 percent following revelations about suspect accounting; chief executive J Michael Pearson had acquired shares amounting to 3 percent of company, largely through compensation, giving him strong incentive to see share price rise.  ", "type_of_material": "News", "word_count": "1122", "lead_paragraph": "Compensation based largely on stock price performance probably played a role in the behavior that led to the drug company\u2019s rise and stunning fall.", "pub_date": "2016-04-05T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant Is a Reminder of the Peril of Outsize Executive Pay", "content_kicker": "Compensation", "print_headline": "Among Causes of Valeant\u2019s Tumble,  Outsize Executive Pay Shares Blame", "kicker": "The Upshot"}, "snippet": "Compensation based largely on stock price performance probably played a role in the behavior that led to the drug company\u2019s rise and stunning fall.", "multimedia": [{"height": 126, "url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/04/05/upshot/05UP-Compensate/05UP-Compensate-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/04/05/upshot/valeant-is-a-reminder-of-the-peril-of-outsize-executive-pay.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Pearson, John Michael (1959- )", "name": "persons"}, {"rank": "3", "is_major": "Y", "value": "Executive Compensation", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Income Inequality", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Boards of Directors", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Stock Options and Purchase Plans", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "57025f2838f0d81980921b09", "source": "The New York Times"}